Autistic disorder

The Medical Basis of Psychiatry: Third Edition

Volumn , Issue , 2008, Pages 355-373

  Realmuto, George M ^a   Azeem, Muhammad W ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Assessment; Autism; Genetics; Histology; Neuronal proteins; Treatment

Indexed keywords

EID: 70449638557     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-252-6_20     Document Type: Chapter

References (206)

1. Kanner L, Autistic disturbance of affective contact. Nerv Child 1943;2:217-250.
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed, text revision. Washington DC: American Psychiatric Association, 2000.
3. The ICD-10 Classification of Mental and Behavioral Disorders: Diagnostic Criteria for Research. Geneva: World Health Organization, 1993.
4. Volkmar FR, Klin A, Siegel B, Szatmari P, Lord C, Campbell M, Freeman BJ, Cicchetti DV, Rutter M, Kline W. Field trial for autistic disorder in DSM-IV Am J Psychol 1994;151: 1361-1367.
5. Cohen DJ, Volkmar F, Anderson G, Klin A. Integrating biological and behavioral perspectives in the study and care of autistic individuals: the future. Isr J Psychiatry Relat Sci 1993;30: 15-32.
6. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994;24:659-685.
7. Lord C, Pickles A, McLennan J, Rutter M, Bregman J, Folstein S, Fombonne E, Leboyer M, Minshew N. Diagnosing autism: analyses of data from the Autism Diagnostic Interview. J Autism Dev Disord 1997;27:501-517.
8. Lord C, Risi S, Lambrecht L, Cook EH Jr, Leventhal BL, DiLa-vore PC, Pickles A, Rutter M. The Autism Diagnostic Observation Schedule-Generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord 2000;30:205-223.
9. Berument SK, Starr E, Pickles A, Tomlins M, Papanikolauou K, Lord C, Rutter M. Pre-linguistic Autism Diagnostic Observation Schedule adapted for older individuals with severe to profound mental retardation: a pilot study. J Autism Dev Disord 2005;35:821-829.
10. Wadden NP, Bryson SE, Rodger RS. A closer look at the Autism Behavior Checklist: discriminant validity and factor structure. J Autism Dev Disord 1991;21:529-541.
11. Volkmar FR, Cicchetti DV, Dykens E, Sparrow SS, Leckman JF, Cohen DJ. An evaluation of the Autism Behavior Checklist. J Autism Dev Disord 1988;18:81-97.
12. Marteleto MR, Pedromonico MR. Validity of autism behavior checklist. Revista Brasileira de Psiquiatria 2005;27:295-301.
13. Rellini E, Tortolani D, Trillo S, Carbone S, Montecchi F. Childhood Autism Rating Scale (CARS) and Autism Behavior Checklist (ABC) correspondence and conflicts with DSM-IV criteria in diagnosis of autism. J Autism Dev Disord 2004;34:703-708.
14. Gilliam J E Gilliam Autism rating Scale, TX PRO-ED, 1995.
15. Stone, WL, Coonrod EE, Pozdol SL, Turner LM, The Parent Interview for Autism-clinical version (PIA CV): A measure of behavioral change for young children with autism. Autism 2003;7:9-30.
16. Tsatsanis KD, Dartnall B, Cuicchetti D, Sparrow SS, Klin A, Volkmar FR. Concurrent validity and classification accuracy of the Leiter and Leiter-R in low functioning children with autism. J Autism Dev Disord 2003;33:23-30.
17. Bishop DVM, Baird G. Parent and teacher report of pragmatic aspects of communication: Use of the Children's Communication Checklist in a clinical setting. Dev Med Child Neurol 2001;43:809-818.
18. Sparrow S, Balla D, Cecchetti D. Vineland Adaptive Behavior Scales, Circle Pines MN: American Guidance Service, 1984.
19. Lord C, Leventhal B, Cook E. Quantifying the phenotype in autism spectrum disorders. Am J Med Genetics 2001;105: 36-38.
20. Folstien S, Rutter M. Infantile autism: A genetic study of 21 twin pairs. J Child Psychol Psychiatry 1977;18(4):297-321.
21. Steffenburg S, Gillberg C, Hellgren L, Andersson L, Gill-berg IC, Jakobsson G, Bohman M. A twin study of autism in Denmark, Finland, Iceland, Norway and Sweden. J Child Psychol Psychiatry 1989;30:405-416.
22. Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, Yuzda E, Rutter M. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med 1995;25: 63-77.
23. Veensra-VanderWeele J, Christian SL, Cook JIH. Autism as a paradigmatic Complex Genetic Disorder. Annu Rev Genomics Hum Genet 2004;5:397-405.
24. Pickels A, Bolton P, Macdonald H et al. Latent-class analysis of recurrence risks for complex phenotypes with selection and measurement error: A twin and family history study of autism. Am J Hum Genet 1995;57:717-726.
25. International Molecular Genetic Study of Autism Consortium. A full genome screen for autism with evidence for linkage to a region on chromosome 7q: Hum Mol Genet 1998;7:571-578.
26. International Molecular Genetic Study of Autism Consortium. A genome-wide screen for autism: strong evidence for linkage to chromosomes 2q, 7q and 16p. Am J Hum Genet 2001;69:570-581.
27. Steele MM, Al-Adeimi M, Siu VM, Fan YS. Brief report: A case of autism with interstitial deletion of chromosome 13: J Autism Dev Disorder 2001;31:231-234.
28. McCauley JL, Li C, Jiang L, Olson LM, Crocket GT, Gainer K, Folstein SE, Haines JL, Sutcliffe JS. Genome-wide and Ordered-Subset Linkage analyses provide support for autism loci on 17q and 19p with evidence of phenotypic and interlocus genetic correlates. BMC Medical Genetics 2005; 6:1.
29. Shao Y, Wolpert CM, Raiford KL, Menold MM, Donnelly SL, Ravan SA, Bass MP, McClain C, von Wendt L, Vance JM, Abramson RH, Wright HH, Ashley-Koch A, Gilbert JR, Delong RG, Cuccaro ML, Pericak-Vance MA, McCoy PA. Genomic screen and follow up analysis for autistic disorder. AM J Med Genet 2002;114B:99-105.
30. Philippe A, Martinez M, Guilloud-Batalle M, Gillberg C, Rastam M, Sponheim E, Coleman M, Zappella M, Aschauer H, van Malldergerme L, Penet C, Feingold J, Brice A, Leboyer M. Genome-wide scan for autism susceptibility genes. Hum Mol Genet 1999;8:805-812.
31. Buxbaum JD, Silverman J, Keddache M, Smith CJ, Hollander E, Ramoz N, Reichert JG. Linkage analysis for autism in a subset of families with obsessive-compulsive behavior: evidence for an autism susceptibility gene on chromosome 1 and further support for susceptibility genes on chromosome 6 and 19. Mol Psychiatry 2004;9:144-150.
32. Van den Veyver IB, Zoghbi HY. Genetic basis of Rett syndrome. Mental Retard Dev Disabil Res Rev 2002;8:82-86.
33. Kjelgaard MM, Tager-Flusberg H. An investigation of language impairment in autism: Implications for genetic subgroups. Lang Cogn Processes 2001;16:287-308.
34. Bartlett CW, Flax JF, Logue MW, Smith BJ, Vieland VJ, Tallal P, Brzustowicz LM. Examination of potential overlap in autism and language loci on chromosomes 2, 7, and 13 in two independent samples ascertained for specific language impairment. Hum Hered 2004;57:10-20.
35. Gottesman I, Gould T. The endophenotype concept in psychiatry. Etymology and strategic intentions. Am J Psychiatry 2003;160:4 636-645.
36. Rutter M, Bailey A, Bolton P, Le Couteur A. Autism and known medical conditions: myth and substance. J Child Psychol Psychiatry 1994;35:311-322.
37. Klauck SM, Munstermann E, Bieber-Martig B. Molecular genetic analysis of the FMR-1 gene in a large collection of autistic patients. Hum Genet 1997;100:224-229.
38. Gutierrez GC, Smalley SL, Tanguay PE. Autism in tuberous sclerosis complex. J Autism Dev Disord 1998;28: 97-103.
39. Jacobsen J, King BH, Leventhal BL, et al. Molecular screening for proximal 15q abnormalities in a mentally retarded population. J Med Genet 1998;35:534-538.
40. Steffenburg S, Gillberg CL, Steffenburg U. Autism in Angelman syndrome: a population-based study. Pediatr Neurol 1996;14:131-136.
41. American College of Obstetrics and Gynecologists Committee on Genetics. ACOG committee opinion: Screening for fragile x syndrome. Obs Gyne 2006;107:1483-1485.
42. Murray J, Cuckle H, Taylor G, Hewison J. Screening for fragile X syndrome. Health Tech Assess 1997;1:1-71.
43. Bailey DB Jr, Mesibov GB, Hatton DD, Clark RD, Roberts JE, Mayhew L. Autistic behavior in young boys with fragile X syndrome. J Autism Dev Disord 1998;28:499-508.
44. Hagerman R. Medical aspects of the fragile X syndrome. In: The Fragile X Child, Singular Publishing Group 1992: 19-29.
45. Hallmayer J, Pintado E, Lotspeich L, Spiker D, McMahon W, Petersen PB, Nicholas P, Pingree C, Kraemer HC, Wong DL. Molecular analysis and test of linkage between the FMR-1 gene and infantile autism in multiplex families. Am J Hum Genet 1994;55:951-959.
46. Piven J, Gayle J, Landa R, Wzorek M, Folstein S. The prevalence of fragile X in a sample of autistic individuals diagnosed using a standardized interview. J Am Acad Child Adolescent Psychiatry 1991;30:825-830.
47. Payton JB, Steele MW, Wenger SL, Minshew NJ. The fragile X marker and autism in perspective. J Am Acad Child Adolescent Psychiatry 1989;28:417-421.
48. Septer S, Thompson ES, Willemsen-Dunlap A. Anesthesia concerns for children with tuberous sclerosis. AANA Journal 2006;74:219-225.
49. Wiznitzer M. Autism and tuberous sclerosis. J Child Neurology 2004;19:675-679.
50. Smalley SL. Autism and tuberous sclerosis. J Autism Dev Disord 1998;28:407-414.
51. Baker P, Piven J, Sato Y. Autism and tuberous sclerosis complex: prevalence and clinical features. J Autism Dev Disord 1998;28:279-285.
52. Starr EM, Berument SK, Tomlins M, Papnikolaou K, Rutter M. Brief report: autism in individuals with down syndrome. J Autism Dev Disord 2005;35:665-673.
53. Kroeger KA, Nelson WM. A language program to increase the verbal production of a child dually diagnosed with down syndrome and autism. J Intellectual Disability Research 2006;50:101-108.
54. Rasmussen P, Borjesson O, Wentz E, Gillberg C. Autistic disorders in down syndrome: background factors and clinical correlates. Dev Med Child Neurol 2001;43:750-754.
55. Marui T, Hashimoto O, Nanba E, Kato C, Tochigi M, Umekage T, Ishijima M, Kohda K, Kato N, Sasaki T. Association between the neurofibromatosis-1 (NF1) locus and autism in the Japanese population. Am J Med Genet 2004;131:43-47.
56. Mbarek O, Marouillat S, Martineau J, Barthelemy C, Muh JP, Andres C. Association study of the NF1 gene and autistic disorder. Am J Med Genet 1999;88:729-732.
57. Plank SM, Copeland-Yates SA, Sossey-Alaoui K, Bell JM, Schroer RJ, Skinner C, Michaelis RC. Lack of association of the (AAAT)6 allele of the GXAlu tetranucleotide repeat in intron 27b of the NF1 gene with autism. Am J Med Genet 2001;105:404-405.
58. Smith AC, McGavran L, Robinson J, Waldstein G, Macfarlane J, Zonona J, Reiss J, Lahr M, Allen L, Magenis E. Interstitial deletion of (17)(P11.2p11.2) in nine patients. Am J Med Genet 1986;24:393-414.
59. Hobson RP, Bishop M. The pathogenesis of autism: insights from congenital blindness. Philosophical Transactions of the Royal Society of London-Series B: Biological Sciences 2003;358:335-344.
60. Carvill S. Sensory impairments, intellectual disability and psychiatry. J Intellectual Disability Res 2001;45:467-483.
61. Hobson RP, Lee A, Brown R. Autism and congenital blindness. J Autism Dev Disord 1999;29:45-56.
62. Brown R, Hobson RP, Lee A, Stevenson J. Are there "autistic like" features in congenitally blind children? J Child Psychol Psychiatry 1997;38:693-703.
63. Deggouj N, Eliot MM. Autistic like behavioural disorders and deafness in children (French). Revue de Laryngologie Otologie Rhinologie 2005;126:365-367.
64. Gayda M, Saleh D. Peripheral, central and psychic deafness: diagnosis difficulties in case of autism child (French). Revue de Laryngologie Otologie Rhinologie 2004;125:277-280.
65. Roper L, Arnold P, Monteiro B. Co-occurrence of autism and deafness: diagnostic considerations. Autism 2003;7:245-253.
66. Rosenhall U, Nordin V, Sandstrom M, Ahlsen G, Gillberg C. Autism and hearing loss. J Autism Dev Disord 1999;29: 349-357.
67. Piven J, Arndt S, Bailey J, Havercamp S, Andreasen N, Palmer P. An MRI study of brain size in autism. Am J Psychiatry 1995;152:1145-1149.
68. Hardan AY, Minshew NJ, Mallikarjuhn M, Keshavan MS. Brain Volume in Autism. J Child Neurol 2001;16:421-424.
69. Hardan AY, Minshew N, Harenski K, Keshavan MS. Posterior fossa magnetic resonance imaging in autism. J Am Acad Child Adolesc Psychiatry 2001;40:666-672.
70. Piven J, Arndt S, Bailey J, Andreasen N. Regional brain enlargement in autism: a magnetic resonance imaging study. J Am Acad Child Adolesc Psychiatry 1996;35:330-536.
71. Courchesne E, Karns CM, Davis HR, Ziccardi R, Carper RA, Tigue ZD, Chisum HJ, Moses P, Pierce K, Lord C, Lincoln AJ, Pizzo S, Schreibman L, Hass RH, Akshoomoff NA, Courchesne RY. Unusual brain growth patterns in early life in patients with autistic disorder, An MRI study. Neurology 2001;57:245-254.
72. Kates W, Burnette C, Eliez S, Strunge LA, Kaplan D, Landa R, Reiss A Perlson GD. Neuroanatomic variation in monozygotic twin pairs discordant for the narrow phenotype for autism. Am J Psychiatry 2004;161:539-546.
73. Castelli F, Frith C, Happe F, Frith U. Autism, Asperger syndrome and brain mechanisms for the attribution of mental states to animated shapes. Brain 2002;125:1839-1849.
74. Frances A, Krams M, Ashburner J, Passingham R, Friston K, Frackowiak R, Happe F, Frith C, Frith U. The neuroanatomy of autism: a voxel-based whole brain analysis of structural scans. NueorReport 1999;10(8):1647-1651.
75. Happe F, Ehlers S, Fletcher P, Frith U, Johansson M, Gillberg C, Dolan R, Frackowiak R, Frith C. 'Theory of mind' in the brain. Evidence from a PET scan study of Asperger syndrome. Neuroreport 1996;8(1):197-201.
76. Courchesne E, Townsend J, Saitoh O. The brain in infantile autism: posterior fossa structures are abnormal. Neurology 1994;44(2):214-223.
77. Bauman ML, Kemper TL Neuroanatomic observations of the brain in autism. In: Bauman ML, Kemper TL, eds. The Neurobiology of Autism. Baltimore: Johns Hopkins Press, 1994: 119-145.
78. Bauman M, Kemper TL. Neuroanatomic observations of the brain in autism: a review and future directions, Int J Dev Neurosci 2005;23:183-187.
79. Fatemi SH, Halt AR, Earle J, Kist DA, Realmuto GM, Thuras PD, Merz A Reduced Purkinje cell size in autistic cerebellum. Cell Mol Neurobiol 2002;22(2):171-175.
80. Arin ML, Bauman M, Kemper TL. The distribution of Purkinje cell loss in the cerebellum in autism. Neurology 1991;41(Suppl.):307.
81. Bauman M and Kemper T. Histoanatomic observations of the brain in early infantile autism. Neurology 1985;35:866-874.
82. Raymond ML, Bauman M, Kemper TL. The hippocampus in autism: Golgi Analysis. Acta Neuropathol 1989;91:117-119.
83. Bailey A, Luthert P, Dean A, Harding B, Janota I, Montgomery M, Rutter M, Lantos P. A clinicopathological study of autism. Brain 1998;121:889-905.
84. Casanova MF, Buxhoeveden D, Switala A, Roy E. Mini-columnar pathology in autism. Neurology 2002;58:428-432.
85. Bauman M, Kemper T. Observation of the Purkinje cells in the cerebellar vermis in autism. J Neuropathol Exp Neurol 1996;55:613.
86. Kemper TL, Bauman M. Neuropathology of infantile autism. J Neuropathol Exp Neurol 1998:57:645-652.
87. Bauman ML, Kemper TL. The neurobiology of autism. 2nd ed. Baltimore (MD): The Johns Hopkins University Press, 2005.
88. Palmen SJ, Hulshoff Pol HE, Kemner C, Schnack HG, Sitskoorn MM, Appels MC, Kahn RS, Van Engeland H. Brain anatomy in non-affected parents of autistic probands: a MRI study. Psychol Med 2005;35(10):1411-1420.
89. Fatemi SH, Halt AR, Stary JM, Realmuto GM, Jalali-Mousavi M. Reduction in anti-apoptotic protein Bcl-2 in autistic cerebellum. NeuroReport 2001;12(5):929-933.
90. Araki N, Morimasa T, Sakai T, Tokuoh H, Yyunoue S, Kama M, Miyazaki K, Abe K, Saya HM, Tsugita A. Comparative analysis of brain proteins from p53 deficient mice by two-dimensional electrophoresis. Electrophoresis 2000;21:1880-1889.
91. Fatemi SH, Halt AR. Altered levels of Bcl2 and p53 proteins in parietal cortex reflect deranged apoptotic regulation in autism. Synapse 2001;42:281-284.
92. Fatemi HS, Snow AV, Stary JM, Araghi-Niknam M, Reutiman TJ, Lee S, Brooks A, Pearce D. Reelin signaling is impaired in autism. Biol Psychiatry 2005;57:777-787.
93. Fatemi SH, Emamian ES, Kist D, Sidwell RW, Nakajima K, Akhter P, Shier A, Sheikh S, Bailey K. Defective corticoge-nesis and reduction in Reelin Immunoreactivity in cortex and hippocampus of prenatally infected neonatal mice. Mol Psychiatry 1999;4:145-154.
94. Persico A.M, D'Agruma L, Maiorano N, Totaro A, Militerni R, Bravaccio C, Wassink T, Schneider C, Melmed R, TRillo S, Montecchi R, Palermo M, Pascucci T, Publisi Allegra S, Reichelt K, Conciatori M, Marion R, Quattrocchi C, Baldi A, Zelante L, Gasparini P, Keller F. Reelin gene alleles and haplo-types as a factor predisposing to autistic disorder. Mol Psychiatry 2001;6(2):150-159.
95. Fatemi SH, Stary JM, Halt A, Realmuto G. Dysregulation of Reelin and Bcl-2 in autistic cerebellum. J Autism Dev Disord 2001;31:529-535.
96. Fatemi SH, Stary JM, Egan EA. Reduced blood levels of reelin as a vulnerability factor in pathophysiology of autistic disorder. Cell Mol Neurobiol 2002;22(2):139-152.
97. Rolf LH, Haarmann FY, Grotemeyer KH, Keher H. Serotonin and amino acid content in platelets or autistic children. Alta Psychiatr Scand 1993;87:312-316.
98. Moreno-Fuenmayer H, Borjas L, Arrieta A, Valera V, Socorro-Candanoza L. Plasma excitatory amino acids in autism. Invest Clin 1996;37:113-128.
99. Fatemi SH, Halt AR, Stary J, Kenodio R, Schulz SC, Realmuto GM. Glutamic acid decarboxylase 65 and 67 k Da proteins are reduced on autistic parietal and cerebellar cortices. Biol Psychiatry 2002;52:805-810.
100. Blatt GJ. GABAergic cerebellar system in autism: a neuropathological and developmental perspective. Int Rev Neurobiol 2005;71:167-178.
101. Blatt GJ, Fitzgerald CM, Guptill JT, Booker AB, Kemper TL. Density and distribution of hippocampal neurotrans-mitter receptors in autism. J Autism Dev Disorder 2001;31: 537-543.
102. Vargas DL, Nascimbene C, Krishnan C, Aimmerman AW, Pardo CA. Nerogligla activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005;57:67-81.
103. Pliopys AV, Greaves A, Yoshida W. Anti CNS antibodies in childhood neurologic diseases. Neuropediatrics 1989;20: 93-102.
104. Ahlsen G, Rosengren L, Belfrage M, et al. Glial fibrillary acidic protein in the cerebrospinal fluid of children with autism and other neuropsychiatric disorders. Biol Psychiatry 1993;33: 734-743.
105. Laurence JA, Fatemi SH. Glial fibrillary acidic protein is elevated in superior frontal, parietal and cerebellar cortices of autistic subjects. Cerebellum 2005;4:206-210.
106. Todd RD, Ciaranello RD. Demonstration of inter-and intro-species differences in serotonin binding sites by antibodies from an autistic child. Proc Natl Acad Sci USA 1985;82:612-616.
107. Shi L, Fatemi SH, Sidwell TW et al. Maternal influenza infection causes marked behavior and pharmacological changes in the offspring. J Neurosci 2003;23:297-302.
108. Warren RP, Foster A, Margaretten NC. Reduced natural killer cell activity in autism. J Am Acad Child Adolesc Psychiatry 1987;26:333-335.
109. Gupta S, Aggarwal S, Rashanravan R, et al. TH1-and TH2-like cytokines in CD4+ and CD8+ T cells in autism. J Neuroim-munol 1998;85:106-109.
110. Kagan-Kushnir T, Roberts SW, Snead OC. Screening electroencephalogram in autism spectrum disorders: evidence-based guideline. J Child Neurol 2005;20:197-206.
111. Kim HL, Donnelly JH, Tournay AE, Book TM, Filipek P. Absence of seizures despite high prevalence of epileptiform EEG abnormalities in children with autism monitored in a tertiary care center. Epilepsia 2006;47:394-398.
112. Chez MG, Chang M, Krasne V, Coughlan C, Kominsky M, Schwartz A. Frequency of epileptiform EEG abnormalities in a sequential screening of autistic patients with no known clinical epilepsy from 1996 to 2005. Epilepsy Behavior 2006;8: 267-271.
113. Reinhold JA, Molloy CA, Manning-Courtney P. Electroencephalogram abnormalities in children with autism spectrum disorders. J Neurosci Nurs 2005;37:136-138.
114. Canitano R, Luchetti A, Zappella M. Epilepsy, electroen-cephalogramic abnormalities, and regression in children with autism. J Child Neurol 2005;20:27-31.
115. Hughes JR, Melyn M. EEG and seizures in autistic children and adolescents: further findings with therapeutic implications. Clinical EEG Neuroscience 2005;36:15-20.
116. Hashimoto T, Sasaki M, Sugai K, Hanaoka S, Fukumizu M, Kato T. Paroxysmal discharges on EEG in young autistic patients are frequent in frontal regions. J Med Investig 2001;48:175-180.
117. Hrdlicka M, Komarek V, Propper L, Kulisek R, Zumrova A, Faladova L Havlovicova M, Sedlacek Z, Blatny M, Urbanek T. Not EEG abnormalities but epilepsy is associated with autistic regression and mental functioning in childhood autism. Eur Child Adolesc Psychiatry 2004;13:209-213.
118. Yeargin-Allsopp M, Rice C. Karapurkar T, Doernberg NH, Boyle C, Murphy C. Prevalence of autism in a US Metropolitan Area. JAMA 2003;289:45-55.
119. Fombonne E. The epidemiology of autism: a review. Psychol Med 1999;29:769-786.
120. Lotter V. Methodological problems in cross-cultural epidemio-logic research: illustrations from a survey of childhood autism in Africa. In: Earls F, ed. Studies of Children. New York: Neale Watson, 1980:126-144.
121. Fombonne E. The prevalence of autism. JAMA 2003;289: 87-89.
122. Centers for Disease Control and Prevention (CDC). Mental health in the United States: parental report of diagnosed autism in children aged 4-17 years-United States, 2003-2004. MMWR 2006;55(17):481-486.
123. Fombonne E. Epidemiological surveys of autism and other pervasive developmental disorders: an Update. J Autism Dev Disord 2003;33:365-382.
124. Fombonne E. The prevalence of autism. JAMA 2003;289: 87-89.
125. Jick H, Kaye JA. Epidemiology and possible causes of autism. Pharmacotherapy 2003;23:1524-1530.
126. Horton R. The lessons of MMR. Lancet 2004;363:747-749.
127. Wakefield AJ. MMR vaccination and autism. Lancet 1999: 949-950.
128. Wakefield AJ, Anthony A, Murch SH, et al. Enterocolitis in children with developmental disorders. Am J Gastroenterol 2000;95:2285-2295.
129. Ashwood P, Anthony A, Pellicer Aa, Torrente F, Walker-Smigth JA, Wakefield AJ. Intestinal lymphocyte populations in children with regressive autism: evidence for extensive mucosal immunopathology. J Clin Immunol 2003;23:504-517.
130. Furlano RI, Anthony A, Day R. Clonic CD8 and gamma delta T-cell infiltration with epithelial damage in children with autism. J Pediatr 2001;138:366-372.
131. Kawashima H, Mori T, Kashiwagi Y, Takekuma K, Hoshika A Wakefield A. Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism Dig Dis Sci 2000;45:723-729.
132. Martin CM, Uhlmann V, Killalea A, Sheils O, O'Leary JJ. Detection of measles virus in children with ileo-colonic lymphoid nodular hyperplasia, enterocolitis and developmental disorder. Mol Psychiatry 2002;7:S47-S48.
133. O'Leary JJ, Uhlmann V, Wakefield AJ. Measles virus and autism. Lancet 2000;356(9231):772.
134. Hendrickson BA, Turner JR. MMR vaccination, ileal lymphoid nodular hyperplasia, and pervasive developmental disorder. Lancet 2002;359:2051-2052.
135. Morris DL, Montgomery SM, Thompson NP, Ebrahim S, Pounder RE, Wakefield AJ. Measles vaccination and inflammatory bowel disease: a national British Cohort Study. Am J Gastroenterol 2000;95:3507-3512.
136. Masden KM, Hviid A, Vestergaarde M, et al. A population-based study of measles, mumps and rubella vaccination and autism. N Engl J Med 2002;347:1477-1482.
137. Smeeth L, Cook C, Fombonne PE, Heavey L, Rodrigues LC, Smith PG, Hall AJ. Rate of first recorded diagnosis of autism and other pervasive developmental disorders in United Kingdom general practice, 1988 to 2001. BMC Med 2004;2:39.
138. Pichichero ME, Cernichiari E, Lopreiato J, Treanor J. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study Lancet 2002;360:1737-1741.
139. Geier MR, Geier DA. Neurodevelopmental disorders after thimerosal containing vaccines: A brief communication. Exp Biol Med 2003;228:660-664.
140. Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Association between thimerosal-containing vaccine and autism. JAMA 2003;290(13):1763-1766.
141. Verstraeten T, Davis RL, De Stegano F, Lieuta, Rhodes PH, Back SB, Shinefield H, Chen RT. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization date bases. Pediatrics 2003;112(5):1039-1048.
142. Jick H, Kaye JA. Autism and DPT vaccination in the United Kingdom. N Engl J Med 2004;350:2722-2723.
143. Stehr-Green P, Tull P, Stellfeld M, Mortenson P-B, Simpson D. Autism and thimerosal containing vaccines: lack of consistent evidence for an association. Am J Prev Med 2003;25:101-106.
144. Volkmar F, Cook E Jr, Pomeroy J, et al. Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 1999;38(12 suppl): 32S-54S.
145. Charlop-Christy MH, Carperter M, LeBlanc LA, Kellet K. Using the picture exchange communication system (PECS) with children with autism, Assessment of PECS acquisition, speech, social-communicative behavior and problem behavior. J Appl Behav Anal 2002;35:213-231.
146. Sundberg CT, Sundberg ML. Comparing topography based verbal behavior with stimulus selection-based verbal behavior Anal Verbal Behav 1990;8:31-42.
147. Lovaas OI, Berberich JP, Perloff BF. Acquisition of imitative speech in schizophrenic children. Science 1966;151:705-707.
148. Lovaas OI, Smith T. A comprehensive behavior theory of autistic children: Paradigm for research and treatment. J Behav Ther Exp Psychiatry 1989;20:17-29.
149. Gray C. The New Social Stories Book. Arlington, TX: Future Horizons, 2000.
150. Zanolli, KJ, Daggert J, Adams T. Teaching preschool age autistic children to make spontaneous initiations to peers using priming. J Autism Dev Disord 1996;26:407-422.
151. Schreibman L, Whalen L. The use of video priming to reduce disruptive transition behavior in children with autism. J Posit Behav Interv 2000;2:3-14.
152. Pierce KL, Schreibman L. Increasing complex social behaviors in children with autism: Effects of peer-implemented pivotal response training. J Appl Behav Anal 1995;27:471-481.
153. Aman MG, Lam KS, Collier-Crespin A. Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. J Autism Dev Disord 2003;33:527-534.
154. Langworthy-Lam KS, Aman MG, Van Bourgondien ME. Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. J Child Adolesc Psychopharmacol 2002;12:311-321.
155. Martin A, Scahill L, Klin A, Volkmar FR. Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use. J Am Acad Child Adolesc Psychiatry 1999;38:923-931.
156. Di Martino A, Melis G, Cianchetti C, Zuddas A. Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open pilot study. J Child Adolesc Psychopharmacol 2004;14:207-218.
157. Hadden BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 2000;30:245-255.
158. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005;62:1266-1274.
159. Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, Iyengar R. A placebo controlled trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005;30:582-589.
160. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996;53:1001-1008.
161. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 1993;50:441-447.
162. DeLong GR, Ritch CR, Burch S. Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. Dev Med Child Neurol 2002;44:652-659.
163. DeLong GR, Teague LA, McSwain Kamran M. Effects of fluoxetine treatment in young children with idiopathic autism. Dev Med Child Neurol 1998;40:551-562.
164. Fatemi SH, Realmuto GM, Khan L, Thuras P. Fluoxetine in the treatment of adolescent patients with autism: a longitudinal open trial. J Autism Dev Disord 1998;28:303-307.
165. McDougle CJ, Brodkin ES, Naylor ST, Carlson DC, Cohen DJ, Price LH. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol 1998;18:62-66.
166. Hellings JA, Kelley LA, Gabrielli WF, Kilgore E, Shah P. Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry 1996;57:333-336.
167. Namerow LB, Thomas P, Bostic JQ, Prince J, Monuteaux MC. Use of citalopram in pervasive developmental disorders. J Develop Behav Pediatrics 2003;24:104-108.
168. Couturier JL, Nicolson R. A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2002;12: 243-248.
169. Owley T, Walton L, Salt J, Guter SJ Jr, Winnega M, Leventhal BL, Cook EH Jr. An open-label trial of escitalopram in pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2005;44:343-348.
170. Garber HJ, McGonigle JJ, Slomka GT, Monteverde E. Clomipramine treatment of stereotypic behaviors and self-injury in patients with developmental disabilities. J Am Acad Child Adolesc Psychiatry 1992;31:1157-1160.
171. Lewis MH, Bodfish JW, Powell SB, Golden RN. Clomipramine treatment for stereotypy and related repetitive movement disorders associated with mental retardation. Am J Ment Retard 1995;100:299-312.
172. Anderson LT, Campbell M, Grega DM, Perry R, Small AM, Green WH. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 1984;141:1195-1202.
173. Remington G, Sloman L, Konstantareas M, Parker K, Gow R. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 2001;162:1361-1369.
174. Locascio JJ, Malone RP, Small AM, Kafantaris V, Ernst M, Lynch NS, Overall JE, Campbell M. Factors related to haloperidol response and dyskinesias in autistic children. Psychopharmacol Bull 1991;27:119-126.
175. Campbell M, Armenteros JL, Malone RP, Adams PB, Eisen-berg ZW, Overall JE. Antipsychotic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 1997;36:835-843.
176. Armenteros JL, Adams PB, Campbell M, Eisenberg ZW. Haloperidol-related dyskinesias and pre-and perinatal complications in autistic children. Psychopharm Bull 1995;31: 363-369.
177. Troost PW, Lahuis BE, Steenhuis MP, Ketelaars CE, Buitelaar JK, Van Engeland H, Scahill L, Minderaa RB, Hoekstra PJ. Long term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 2005;11:1137-1144.
178. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychol 2005;162:1361-1369.
179. McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, Arnold LE, Posey DJ, Martin A, Ghuman JK, Shah B, Chuang SZ, Swiezy NB, Gonzalez NM, Hollway J, Koenig K, McGough JJ, Ritz L, Vitiello B. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychol 2005;1142-1148.
180. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004;114: 634-641.
181. Masi G, Cosenza A, Mucci M, Brovedani P. Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2001;40: 1206-1214.
182. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posed D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D. Reasearch Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347:314-321.
183. Potenza MN, Holmes JP, Kanes SJ, McDougle CJ. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open label pilot study. J Clin Psychopharmacol 1999;19:37-44.
184. Malone RP, Cater J, Sheikh RM, Choudary MS, Delaney MA. Olanzapine versus Haldol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 2001;40:887-894.
185. Martin A, Koenig K, Scahill L, Bregman J. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 1999;9: 99-107.
186. Findling RL, McNamara NK, Gracious BL, O'Riordan MA, Reed MD, Demeter C, Blumer JL. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 2004;14:287-294.
187. McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasi-done for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002;41:921-927.
188. Stigler KA, Posey DJ, McDougle CJ. Aripiprazole for maladap-tive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004;14:455-463.
189. Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, Anagnostou E. Divalproex sodium vs. placebo in the treatment of repetitive behaviors in autism spectrum disorder. International J Neuro Psychopharmacol 2006;9:209-213.
190. Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry 2001;62:530-534.
191. Rugino TA, Samsock TC. Levetiracetam in autistic children. J Dev Behav Pediatrics 2002;23:225-230.
192. Belsito KM, Law PA, Kirk KS, Landa RJ, Zimmerman AW. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 2001;31:175-181.
193. Fankhauser MP, Karumanchi VC, German ML, Yates A, Karu-manchi SD. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 1992;53:77-82.
194. Jaselskis CA, Cook EH Jr, Fletcher KE, Leventhal BL. Cloni-dine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 1992;12:322-327.
195. Posey DJ, Puntney JI, Sasher TM, Kem DL, McDougle CJ. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 2004;14:233-241.
196. Ratey JJ, Mikkelsen E, Sorgi P, Zuckerman HS, Polakoff S, Bemporad J, Bick P, Kadish W. Autism: The treatment of aggressive behaviors. J Clin Psychopharmacol 1987;7:35-41.
197. Kolmen BK, Feldman HM, Handen BL, Janosky JE. Naltrexone in young children: a double blind, placebo-controlled crossover study. J Am Acad Child Adolesc Psychiatry 1995;34:223-231.
198. Campbell M, Anderson LT, Small AM, Adams P, Gonzalez NM, Ernst M. Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry 1993;32:1283-1291.
199. Campbell M, Overall JE, Small AM, Sokol MS, Spencer EK, Adams P, Foltz RL, Monti KM, Perry R, Nobler M. Naltrexone in autistic children: an acute open dose range tolerance trial. J Am Acad Child Adolesc Psychiatry 1989;28:200-206.
200. Herman BH, Hammock MK, Arthur-Smith A, Kuehl K, Appelgate K. Effects of acute administration of naltrexone on cardiovascular function, body temperature, body weight and serum concentrations of liver enzymes in autistic children. Develop Pharma Therapeut 1989;12:118-127.
201. Feldman HM, Kolmen BK, Gonzaga AM. Naltrexone and communication skills in young children with autism. J Am Acad Child Adolesc Psychiatry 1999;38:587-593.
202. Willemsen-Swinkles SH, Buitelaar JK, van England H. The effects of chronic naltrexone treatment in young children: a double-blind placebo-controlled crossover study. Biol Psych 1996;39:1023-1031.
203. Willemsen-Swinkles SH, Buitelaar JK, Nijhof GJ, van England H. Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies. Arch Gen Psychiatry 1995;52:766-773.
204. Welch MG, Ruggiero DA. Predicted role of secretin and oxytocin in the treatment of behavioral and developmental disorders: implications for autism. Int Rev Neurobiol 2005;71:273-315.
205. Pfeiffer SI, Norton J, Nelson L, Shott S. Efficacy of vitamin B6 and magnesium in the treatment of autism: a methodology review and summary of outcomes. J Autism Dev Disord 1995;25(5): 481-493.
206. Levy S, Hyman S. Novel treatment for autistic spectrum disorders. Ment Retard Dev Disabil Res Rev 2005;11:131-142.